Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.
Adding the IgG1 monoclonal antibody ramucirumab to docetaxel improved progression-free survival at 5-month follow-up.
Novel genetic aberrations were found in 3% of tumors.
Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.
Adding selective internal radiotherapy to chemotherapy failed to improve survival and increased risk for adverse events.
More intense preoperative chemotherapy fails to improve survival.
The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.
More evidence that in thrombocytopenic patients, platelet count is an imprecise predictor of bleeding.
Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.
Outcomes with haploidentical stem-cell transplantation plus cyclophosphamide were similar to those with matched related or unrelated donor transplantation.
Prof. Dr. med. Florian Otto
Tumor- und Brustzentrum ZeTuP, St. Gallen
E-Mail: E-Mail anzeigen
Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.
Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.
Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.
The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.
Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.
Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.
A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.
Declines in light chain levels were achieved in heavily pretreated patients.
The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.
Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.
Overall survival was significantly better with S-1 versus gemcitabine.